3 recruiting, 1 not yet recruiting. 4 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 3, Not yet recruiting 1 |
| Phase 1 | 3 | Recruiting 2, Not yet recruiting 1 |
Follow Peripheral T Cells Lymphoma (PTCL): new trials by email Literature Review of Peripheral T Cells Lymphoma (PTCL) trials Research Report on Peripheral T Cells Lymphoma (PTCL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL Zeprumetostat, Azacitidine (AZA), Mitoxantrone Hydrochloride Liposome - Peripheral T Cells Lymphoma (PTCL) | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 26 | 2026-01-15 | 2026-01-28 |
| Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma Linperlisib, Chidamide - Peripheral T Cells Lymphoma (PTCL) | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-sen University | 54 | 2025-09-15 | 2025-08-24 |
| A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas roginolisib, golcadomide, azacitidine - Peripheral T Cells Lymphoma (PTCL), Follicular Helper T-Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | The Lymphoma Academic Research Organisation | 80 | 2025-08-20 | 2026-11-06 |
| Polyspecific Antibodies in Lymphoproliferative T-cell Disorders LIS1 - Peripheral T Cells Lymphoma (PTCL) | Phase 1 / Phase 2 | Recruiting | Xenothera SAS | 54 | 2024-07-09 | 2026-08-20 |
Lymphoma (1)
Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
Azacitidine (2) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (1) · venetoclax (1)
Sun Yat-sen University (1) · The First Affiliated Hospital of Soochow University (1) · The Lymphoma Academic Research Organisation (1) · Xenothera SAS (1)
France (2) · China (1) · Italy (1)
2023 (1)